Hallucinations

Psychedelic Decriminalization Creating Market Opportunities

Retrieved on: 
Monday, July 12, 2021
Hallucinations, Master of Medicine, Psychedelic drug, Health sciences, Medication, Health, Draft:MindMed, Drug culture

Legalization efforts began with marijuana in 2018, creating a booming market for investors.

Key Points: 
  • Legalization efforts began with marijuana in 2018, creating a booming market for investors.
  • Now, the psychedelics market is in the spotlight, with states across America looking to decriminalize psychedelic mushrooms.
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED)is a clinical-stage psychedelic medicine biotech company that develops psychedelic medicines and therapies for the treatment of mental illness and addiction.
  • COMP360, if approved, could receive up to 11 years of market exclusivity in the EU and US.

MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit

Retrieved on: 
Monday, July 12, 2021
Hallucinations, Psychedelic drug, Master of Medicine, NASDAQ, Finance

MindMed is a clinical-stage biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness.

Key Points: 
  • MindMed is a clinical-stage biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness.
  • MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
  • Forward-looking information in this news release include, but are not limited to, Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit and MindMed's participation in the Virtual Summit.
  • Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market

Retrieved on: 
Wednesday, July 7, 2021
Hallucinations, Entheogens, Hallucinogen, Psychoactive drugs, Branches of biology, Dissociative, Psychedelic drug, Lysergic acid diethylamide, Drugs, Psychedelic music, Psychedelia

Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD.

Key Points: 
  • Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD.
  • According to Data Bridge Market Research, the psychedelic drugs market is expected to gain market growth in the forecast period of 2021 to 2028.
  • The rising prevalence of mental depression and anxiety and availability of off-label drugs are the major drivers which has propelled the demand of the psychedelic drugs market in the forecast period.The report said: "The awareness campaigns have encouraged people to select appropriate treatment for mental disorders procedures and professionals which is increasing the demand of psychedelic drugs and the rising awareness towards mental healthis acting as a driver for the psychedelic drugs market.
  • Increasing research and development expenditure in the psychedelic drugs is creating new opportunities in the psychedelic drugs market, thus increasing R&D activities in psychedelic drugs is acting as an opportunity for the growth of the psychedelic drugs market.

Braxia Scientific to Discuss Psychiatric Treatment Discovery and Development with Oxford University Researchers at AIMday Experimental Medicine in Psychiatry on July 7, 2021

Retrieved on: 
Wednesday, July 7, 2021
Psychoactive drugs, Drugs, Branches of biology, Antidepressants, Hallucinations, Lundbeck, Valby, Ketamine, Major depressive disorder, Psychedelic drug, Circadian rhythm, Psilocybin

Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of "How can we advance treatment discovery and development in psychiatry targeting cognition?"

Key Points: 
  • Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of "How can we advance treatment discovery and development in psychiatry targeting cognition?"
  • Participating companies include: Braxia Scientific, Lundbeck, Compass Pathways, P1vital, Circadian Therapeutics, Zogenix, Cyclica, Precision Life, Beckley Psytech, BrainBerry, Braincures, BrainPatch, Psious, Jazz Pharmaceuticals & Ranvier Health.
  • The medical solutions company aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Inclu

Retrieved on: 
Wednesday, July 7, 2021
Psychoactive drugs, Branches of biology, Hallucinations, Medicine, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Major depressive disorder, Draft:MindMed, Psychedelic therapy

Dr. Ross is an Associate Professor of Psychiatry at NYU Langone, and the Associate Director of its newly designated Center for Psychedelic Medicine.

Key Points: 
  • Dr. Ross is an Associate Professor of Psychiatry at NYU Langone, and the Associate Director of its newly designated Center for Psychedelic Medicine.
  • Dr. Ross research principally focuses on the use of psilocybin and related psychedelics for the treatment of mood disorders in patients with life-threatening cancer.
  • As part of the collaboration, the parties will continue to explore the role of psychedelics in the treatment of mental illness in other life-threatening disorders, in addition to cancer.
  • Importantly, we believe that psilocybin is a promising treatment for anxiety and depression in patients with life-threatening cancer, increasing therapeutic opportunities.

MCOA Subsidiary cDistro Signs Distribution Agreement with Silo Wellness and Marley One Functional Mushrooms 

Retrieved on: 
Tuesday, June 29, 2021
Musicians, Guitarists, Fungi, Hallucinations, Psychedelic drug, Bob Marley, Marley, Mushroom, Psilocybin mushroom

Silo Wellness, a leading global psychedelics company, chosecDistro as one of its first distributors to launch Marley One, the first global functional and psychedelic mushroom consumer brand.

Key Points: 
  • Silo Wellness, a leading global psychedelics company, chosecDistro as one of its first distributors to launch Marley One, the first global functional and psychedelic mushroom consumer brand.
  • Silo has also announced that it intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics.
  • TheMarley family name is an iconic part of our history and were thrilled tobringthese exciting new products into our fast growing distribution portfolio.
  • We have already commenced our marketing efforts tointroduce and distribute Marley One, in collaboration withSilo Wellness and theBob Marley Family.

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Retrieved on: 
Monday, June 28, 2021
Alternative medicine, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Hallucinations, Psychedelic drug, Hallucinogen, Cybin Inc., Adelia, CYBIN INC., ADELIA

Management of Cybin believes that these initial results add value to Cybins pipeline of proprietary novel psychedelic compounds by demonstrating these molecules perform similarly to the naturally occurring molecules in certain important metrics.

Key Points: 
  • Management of Cybin believes that these initial results add value to Cybins pipeline of proprietary novel psychedelic compounds by demonstrating these molecules perform similarly to the naturally occurring molecules in certain important metrics.
  • The development of these compounds differentiates Cybin from companies focused on naturally occurring psychedelic compounds.
  • These positive catalysts continue to provide the necessary data required to demonstrate that Cybins proprietary deuterated psychedelic molecules potentially carry the same pharmacodynamic properties, safety profiles, potency and receptor targeting as their parent molecules.
  • Adelias primary focus is on the development of treatment regimens consisting of proprietary psychedelic molecules and related clinical protocols.

Goodness Growth Holdings Subsidiary Resurgent Biosciences Files Patent for Virtual Reality Applications to Facilitate Therapeutic Psychedelic Experiences

Retrieved on: 
Monday, June 28, 2021
Psychoactive drugs, Drugs, Hallucinations, Entheogens, Psychedelia, Drug discovery, Psychedelic therapy, Psychedelic experience, Psychedelic drug, Medication, VR, MDMA

To address this need, Resurgent is developing a suite of VR applications that will provide customizable environments and programs for psychedelic therapy and the extensive preparation work necessary to optimize therapeutic psychedelic experiences.

Key Points: 
  • To address this need, Resurgent is developing a suite of VR applications that will provide customizable environments and programs for psychedelic therapy and the extensive preparation work necessary to optimize therapeutic psychedelic experiences.
  • "We believe that VR programs allow practitioners to better prepare and guide patients through their experiences and may optimize therapeutic approaches with psychedelic medicines."
  • Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world.
  • The Company's operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences.

Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit Awareness

Retrieved on: 
Friday, June 25, 2021
Hallucinations, Biomarkers, Biology, Branches of biology, Life sciences, Hallucinogen, Psychedelic drug, Biotechnology

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with Maya health PBC ("Maya'') to help drive brand awareness of the Company's Psychedelics Genetic Test kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. ("HaluGen").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with Maya health PBC ("Maya'') to help drive brand awareness of the Company's Psychedelics Genetic Test kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. ("HaluGen").
  • The agreement with Maya is expected to drive awareness and potential sales of HaluGen's genetic test kit, a first-of-its-kind product launched in the U.S. on June 10 and in Canada on April 6.
  • The test kit identifies specific DNA biomarkers to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.
  • "Maya and Entheon share a mutual vision to help create safer psychedelic experiences and help people make informed choices about their treatment.

PSYC Interviews CA Senator Scott Wiener to Discuss Efforts to Legalize Psychedelics

Retrieved on: 
Wednesday, June 23, 2021
Health, Articles, Drug culture, Hallucinations, Psychedelic drug, Mental health, Harm reduction

In my opinion, SB 519 has the potential to serve as an important catalyst for the psychedelic movement across the country, Flores continued.

Key Points: 
  • In my opinion, SB 519 has the potential to serve as an important catalyst for the psychedelic movement across the country, Flores continued.
  • We have a mental health crisis in this country and California is not immune, Said Senator Wiener about SB 519 in his exclusive interview with Psychedelic Spotlight.
  • We know that psychedelics can have significant benefits with people struggling with addiction and mental health challenges.
  • We support a harm reduction approach for the purpose of education and promoting individual and public safety.